<DOC>
	<DOCNO>NCT02093689</DOCNO>
	<brief_summary>The purpose study evaluate effect OMS302 sign Intraoperative Floppy Iris Syndrome patient risk .</brief_summary>
	<brief_title>A Randomized , Placebo-controlled Study Subjects High Risk Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery</brief_title>
	<detailed_description>OMS302 mydriatic/anti-inflammatory combination investigational drug product develop use intraoperative lens replacement ( ILR ) . This study evaluate effect OMS302 sign Floppy Iris Syndrome subject history tamsulosin exposure undergo ILR .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Competent provide inform consent . 2 . Voluntarily provide informed consent HIPAA Authorization accordance local regulation govern IEC/IRB requirement prior procedure evaluation perform specifically sole purpose study . 3 . Indicate understand able , willing , likely fully comply study procedure restriction . 4 . Are male 18 year age old time surgery . 5 . Are undergo unilateral primary ILR , topical anesthesia , insertion intraocular lens . 6 . Have bestcorrected visual acuity ( BCVA ) 20/400 good nonstudy eye . 7 . Have intraocular pressure ( IOP ) 5 mm Hg 22 mm Hg , inclusive , study eye . 8 . Is currently take tamsulosin ( Flomax® ) least six month . 1 . Hypersensitivity phenylephrine , ketoprofen , bromfenac , NSAIDs , include aspirin . 2 . Hypersensitivity tetracaine , lidocaine , ophthalmic viscoelastic device ( hydroxypropylmethylcellulose hyaluronic acid latex.. 3 . Presence clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematological , endocrine , neurological , psychiatric , respiratory medical condition could increase risk subject determine Investigator . 4 . Presence connective tissue disorder ( e.g. , lupus , rheumatoid arthritis , fibromyalgia ) . 5 . Presence systolic blood pressure great 170 mmHg less 90 mmHg , diastolic blood pressure great than110 mmHg le 40 mmHg screen visit . 6 . Use phenylephrine study eye ( screen ophthalmological examination ) within seven day prior day surgery . 7 . Use monoamine oxidase inhibitor within 21 day prior day surgery . 8 . Use pilocarpine study eye within seven day prior day surgery . 9 . Presence narrowangle glaucoma unstable glaucoma . 10 . Glaucoma treat prostaglandin prostaglandin analogue Xalatan® , Lumigan® , Travatan® , Rescula® , Alphagan® ( brimonidine tartrate ) either eye seven day prior screen Day 7 postoperatively . 11 . Presence pseudocapsular exfoliation either eye . 12 . History iritis , ocular trauma iris damage study eye . 13 . Presence uncontrolled chronic ocular disease either eye could affect pupil dilation . 14 . Presence active corneal pathology either eye ( except superficial punctate keratopathy nonstudy eye ) . 15 . Presence extraocular/intraocular inflammation either eye . 16 . Presence active bacterial and/or viral infection either eye . 17 . Participating investigational drug device trial within 30 day prior day surgery . 18 . History intraocular nonlaser surgery study eye within three month prior day surgery , intraocular laser surgery study eye within 30 day prior day surgery . 19 . Presence condition Investigator believe would put subject risk confound interpretation study data . 20 . Investigators , employee investigative site , immediate family . Immediate family define Investigator 's employee ' current spouse , parent , natural legally adopt child ( include stepchild living Investigator 's household ) , grandparent , grandchild . 21 . Prior participation clinical study OMS302 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>